Figure 10 examines the performance of PCA3 score to identify subsequent positive prostate cancer biopsies for nine studies. The X axis represents the false positive rate (1-specificity) and is scaled from 0 to 1. The Y axis represents sensitivity of testing and is also scaled from 0 to 1. A dotted vertical line runs across the figure at a 45 degree angle to show the point at which sensitivity equals 1-specificity and a test would be noninformative. The sensitivity versus the specificity is shown with the points representing all 9 studies falling above the dotted line. Filled circles indicate the studies that focus on the “grey zone” of tPSA.

Figure 10The performance of PCA3 score to identify subsequent positive prostate cancer biopsies from nine studies

Note: The sensitivity (y-axis) versus the false positive rate (1-specificity, x-axis) of PCA3 testing is shown for the nine studies. Filled circles indicate the study that focus on the “grey zone” of tPSA (2.5-10 ng/mL) when enrolling patients. The thin solid lines indicate the 95% confidence intervals of the sensitivity estimates. The solid line is the fitted ROC curve to the provided data. For reference, the dashed line indicates where the sensitivity and 1 - specificity are equal, indicating a useless test.

From: Results

Cover of PCA3 Testing for the Diagnosis and Management of Prostate Cancer
PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet].
Comparative Effectiveness Reviews, No. 98.
Bradley LA, Palomaki G, Gutman S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.